Please login to the form below

Not currently logged in
Email:
Password:

Ikervis

This page shows the latest Ikervis news and features for those working in and with pharma, biotech and healthcare.

NICE no for new eye disease drug

NICE no for new eye disease drug

In a statement NICE said that its independent Appraisal Committee had not been presented with evidence on the relative cost and clinical effectiveness of Ikervis compared with established clinical practice. ... It also wants to see an economic model

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics